title: Chemotherapy in Androgen-Independent Prostate Cancer (AIPC): What's next after taxane progression?
abstract: SummaryProstate cancer is the most common non-cutaneous cancer in the United States. Although most are diagnosed at earlier stages of disease, a significant number of patients will eventually progress to metastatic androgen-independent prostate cancer (AIPC) and will receive chemotherapy. The benefit of chemotherapy in overall survival has been demonstrated in studies utilizing docetaxel. However, duration of response is short and therapeutic options are limited after taxane failure. There is a need for effective chemotherapeutic agents in the second-line setting, either alone or in combination. Some of these regimens may also ultimately translate to the front-line chemotherapeutic setting as an alternative or perhaps in combination with a taxane.
authors: Medical Oncology Branch, National Cancer Institute, National Institutes of Health.
authors: Jeanny B
authors: JB
authors: Aragon-Ching
authors: William L
authors: WL
authors: Dahut
references: Cancer. 2006 Mar 1;106(5):1041-6
references: 16456811
references: BJU Int. 2005 Aug;96(3):296-302
references: 16042717
references: Expert Opin Investig Drugs. 2000 Jun;9(6):1373-82
references: 11060749
references: J Clin Oncol. 2005 Nov 10;23(32):8247-52
references: 16278480
references: J Clin Oncol. 2001 Jan 1;19(1):44-53
references: 11134194
references: Eur J Cancer. 1993;29A(15):2094-6
references: 7507687
references: Cancer. 2003 Feb 1;97(3):561-7
references: 12548597
references: Am J Ther. 2004 Jul-Aug;11(4):288-94
references: 15266221
references: Cancer Pract. 1997 Jul-Aug;5(4):258-63
references: 9250085
references: Jpn J Clin Oncol. 2000 Sep;30(9):377-84
references: 11095134
references: Semin Oncol. 1999 Apr;26(2):162-73
references: 10597727
references: Cancer Chemother Pharmacol. 1998;42(2):142-8
references: 9654114
references: Ann Oncol. 2003 Oct;14(10):1518-24
references: 14504052
references: Oncology. 2005;68(1):2-9
references: 15741753
references: Cancer. 2006 Aug 15;107(4):738-45
references: 16826591
references: Cancer. 2000 Jun 15;88(12 Suppl):3009-14
references: 10898345
references: J Clin Oncol. 2007 Feb 20;25(6):669-74
references: 17308271
references: Am J Clin Oncol. 1983 Apr;6(2):203-5
references: 6681933
references: J Clin Oncol. 1997 Jul;15(7):2691-700
references: 9215842
references: Cancer. 2003 Nov 1;98(9):1842-8
references: 14584065
references: J Clin Oncol. 2005 Mar 1;23(7):1439-46
references: 15735119
references: Proc Natl Acad Sci U S A. 1993 Oct 15;90(20):9552-6
references: 8105478
references: Cancer Chemother Pharmacol. 1995;36(6):451-8
references: 7554035
references: J Clin Oncol. 2005 Dec 1;23(34):8724-9
references: 16314632
references: CA Cancer J Clin. 1972 Jul-Aug;22(4):232-40
references: 4625049
references: Cancer. 2006 Jan 1;106(1):58-62
references: 16329138
references: N Engl J Med. 2006 Sep 7;355(10):983-91
references: 16957145
references: Biochemistry. 2002 Mar 26;41(12):3870-4
references: 11900528
references: N Engl J Med. 2004 Oct 7;351(15):1513-20
references: 15470214
references: Cancer Res. 1994 Aug 1;54(15):4118-22
references: 8033145
references: Br J Cancer. 2004 Apr 5;90(7):1312-7
references: 15054447
references: Cancer Treat Rep. 1986 Apr;70(4):541-2
references: 3698053
references: JAMA. 2005 Jul 13;294(2):238-44
references: 16014598
references: Cancer. 1993 Feb 1;71(3 Suppl):1098-109
references: 7679039
references: J Clin Oncol. 2004 May 15;22(10):2015-25
references: 15143095
references: N Engl J Med. 2004 Oct 7;351(15):1502-12
references: 15470213
references: BJU Int. 2005 Nov;96(7):990-4
references: 16225514
references: Urology. 2006 Jun;67(6):1235-40
references: 16765185
references: Ann Oncol. 1998 Dec;9(12):1315-22
references: 9932162
references: Urology. 1980 Feb;15(2):123-6
references: 7188818
references: J Clin Oncol. 2001 May 1;19(9):2509-16
references: 11331330
references: J Clin Oncol. 1996 Jun;14(6):1756-64
references: 8656243
references: Trends Pharmacol Sci. 1992 Apr;13(4):134-6
references: 1350385
references: Exp Mol Med. 2006 Jun 30;38(3):320-4
references: 16819291
references: Ann Oncol. 1999 Nov;10(11):1307-10
references: 10631457
references: Invest New Drugs. 2005 Jan;23(1):79-84
references: 15528984
references: BJU Int. 2005 Nov;96(7):985-9
references: 16225513
references: J Clin Oncol. 2004 Jul 1;22(13):2532-9
references: 15226321
references: Eur J Cancer. 2002 Aug;38(12):1626-32
references: 12142053
references: CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66
references: 17237035
references: Cancer Treat Rep. 1979 Sep-Oct;63(9-10):1557-64
references: 498155
references: Urology. 1997 Jul;50(1):93-9
references: 9218025
references: Ann Oncol. 2004 Nov;15(11):1613-21
references: 15520061